Actionnariat et activité des initiés pour KalVista Pharmaceuticals, Inc. (KALV): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $27.00 |
| Capitalisation | $1.4B |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $30.9M | $51.1M | $32.0M | $15.8M | $50.6M | $30.7M | $56.2M | $31.8M | $98.6M | $229.3M |
| Placements à Court Terme | 0 | 0 | $68.8M | $51.9M | $198.3M | $135.5M | $93.1M | $178.6M | $89.0M | $70.9M |
| Créances | $2.5M | $6.8M | $11.3M | $16.5M | $11.7M | $16.8M | $18.6M | $10.9M | $15.1M | $11.3M |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.4M |
| Actifs Courants | $34.2M | $59.4M | $115.5M | $88.7M | $264.3M | $193.6M | $172.3M | $225.7M | $241.7M | $320.1M |
| Immobilisations Corporelles | $97000 | $1.8M | $2.4M | $3.7M | $7.5M | $10.0M | $10.8M | $9.1M | $2.0M | $12.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $34.3M | $61.4M | $118.1M | $92.5M | $272.0M | $203.9M | $183.2M | $235.4M | $250.8M | $335.4M |
| Dettes Fournisseurs | $1.2M | $1.4M | $2.9M | $1.7M | $2.0M | $3.6M | $4.8M | $9.1M | $4.9M | $8.3M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Courants | $3.0M | $23.2M | $18.1M | $7.7M | $9.8M | $11.6M | $15.0M | $22.8M | $45.2M | $57.4M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $139.2M |
| Passifs Totaux | $3.0M | $34.1M | $21.4M | $8.8M | $14.8M | $18.8M | $22.2M | $28.8M | $155.4M | $338.1M |
| Réserves | -$55.9M | -$71.7M | -$92.5M | -$121.6M | -$167.8M | -$250.2M | -$343.1M | -$469.7M | -$653.2M | -$762.7M |
| Capitaux Propres | $31.3M | $27.3M | $96.7M | $83.8M | $257.2M | $185.1M | $161.0M | $206.6M | $95.4M | -$2.7M |
| Dette Totale | 0 | $279000 | $54000 | $1.6M | $5.9M | $8.2M | $8.2M | $7.3M | $6.3M | $151.6M |
| Dette Nette | -$30.9M | -$50.8M | -$100.8M | -$66.1M | -$243.0M | -$158.0M | -$141.1M | -$203.1M | -$181.3M | -$148.6M |
| Fonds de Roulement | $31.2M | $36.2M | $97.5M | $81.0M | $254.5M | $182.1M | $157.3M | $202.9M | $196.5M | $262.8M |
Santé financière
| Dette / Capitaux propres | -104.83 |
| Ratio de liquidité | 5.58 |
Rentabilité
| Rentabilité des capitaux propres | -1057.44% |
| Rentabilité du capital investi | -46.81% |
| Rentabilité des actifs | -41.28% |
| Marge brute | 92.03% |
| Marge opérationnelle | -120.80% |
| Marge nette | -119.44% |
Entreprises liées: COGT · KNSA · KRYS · KURA · LRMR · PTGX · SRRK
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de KALV: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions